The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis
Molecular Oncology · 2025-12 · 19 (12) · 3651-3664
DOI: 10.1002/1878-0261.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 19.09.2025. Verfasst von Michela De Meo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Sapienza University of Rome, Italy. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union - Next Generation EU, PNRR-RT_SPOKE_1-ROME TECHNOPOLE, Association for Cancer Research, AIRC IG, HEAL ITALIA.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a leading cause of cancer‐related mortality, with metastatic CRC (mCRC) posing significant challenges due to tumor heterogeneity and resistance to therapy. Circulating tumor cells (CTC) and circulating hybrid cells (CHC) detected via liquid biopsies have emerged as promising biomarkers for monitoring disease progression. This study aimed to evaluate the prognostic utility of automated CTC enumeration using the ACCEPT software compared to a manual method and assess the potential clinical relevance of CHC in mCRC. A retrospective analysis of CellSearch ® images from 67 mCRC patients was conducted, correlating CTC and CHC counts with progression‐free survival and overall survival (OS). Automated enumeration demonstrated improved accuracy and reduced variability, confirming the prognostic significance of CTC counts for OS. However, CHC enumeration showed no significant association with clinical outcomes, suggesting sporadic detection rather than consistent prognostic value. These findings underscore the reliability of automated CTC enumeration in mCRC prognosis while highlighting the need for further research into the biological and clinical roles of CHC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine, Sapienza University of Rome, Italy.
- Medical Oncology, Sant'Andrea University Hospital, Rome, Italy.
- Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
- Cancer Liquid Biopsy Unit, Department of Experimental Medicine, Sapienza University of Rome, Italy.
- Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
ORCID-Profile: Michela De Meo, Marco Siringo
Förderung
- European Union - Next Generation EU, PNRR-RT_SPOKE_1-ROME TECHNOPOLE
- Association for Cancer Research, AIRC IG
- HEAL ITALIA
- European Union - Next Generation EU, PNRR-MAD-2022
Zitieren
APA
De Meo, M., Siringo, M., Vici, A., Zeuner, A., Gandini, O., Gazzaniga, P., & Nicolazzo, C. (2025). The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis. Molecular Oncology, 19(12), 3651-3664. https://doi.org/10.1002/1878-0261.70126
Vancouver
De Meo M, Siringo M, Vici A, Zeuner A, Gandini O, Gazzaniga P, et al. The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis. Molecular Oncology. 2025;19(12):3651-3664. doi:10.1002/1878-0261.70126
BibTeX
@article{DeMeo2025,
author = {De Meo, Michela and Siringo, Marco and Vici, Alessandro and Zeuner, Ann and Gandini, Orietta and Gazzaniga, Paola and Nicolazzo, Chiara},
title = {The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {12},
pages = {3651--3664},
doi = {10.1002/1878-0261.70126}
}
EUVIMED